DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report sent to investors on Tuesday. The firm issued a hold rating on the stock.

DBVT has been the subject of several other reports. HC Wainwright increased their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday, October 24th. JMP Securities restated a “market outperform” rating and issued a $10.00 target price on shares of DBV Technologies in a research note on Tuesday, December 10th.

DBV Technologies Trading Down 2.0 %

Shares of NASDAQ:DBVT opened at $2.98 on Tuesday. The company has a market capitalization of $61.30 million, a PE ratio of -0.66 and a beta of 0.64. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $10.70. The business’s fifty day simple moving average is $3.39 and its 200-day simple moving average is $3.94.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.